N
Nobuo Hanai
Researcher at Kyowa Hakko Kirin Co., Ltd.
Publications - 190
Citations - 8171
Nobuo Hanai is an academic researcher from Kyowa Hakko Kirin Co., Ltd.. The author has contributed to research in topics: Antibody & Monoclonal antibody. The author has an hindex of 40, co-authored 188 publications receiving 7961 citations. Previous affiliations of Nobuo Hanai include National Institute of Water and Atmospheric Research & Oita University.
Papers
More filters
Journal ArticleDOI
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity.
Toyohide Shinkawa,Kazuyasu Nakamura,Naoko Yamane,Emi Shoji-Hosaka,Yutaka Kanda,Mikiko Sakurada,Kazuhisa Uchida,Hideharu Anazawa,Mitsuo Satoh,Motoo Yamasaki,Nobuo Hanai,Kenya Shitara +11 more
TL;DR: The results indicate that the lack of fucosylation of IgG1 has the most critical role in enhancement of ADCC, although several reports have suggested the importance of Gal or bisecting GlcNAc and provide important information to produce the effective therapeutic antibody.
Patent
Method for controlling the activity of immunologically functional molecule
Nobuo Hanai,Kazuyasu Nakamura,Emi Shoji,Motoo Yamasaki,Kazuhisa Uchida,Toyohide Shinkawa,Susumu Imabeppu,Yutaka Kanda,Naoko Yamane,Hideharu Anazawa +9 more
TL;DR: A method for controlling the activity of an immunologically functional molecule such as an antibody, a protein or a peptide is described in this paper, where a promoter of the activity is defined.
Journal ArticleDOI
Ganglioside-mediated modulation of cell growth. Specific effects of GM3 and lyso-GM3 in tyrosine phosphorylation of the epidermal growth factor receptor.
TL;DR: It is possible that de-N-fatty acylation of gangliosides could be an effective means to modulate EGF receptor function in membranes.
Journal ArticleDOI
Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma
Rinpei Niwa,Emi Shoji-Hosaka,Mikiko Sakurada,Toyohide Shinkawa,Kazuhisa Uchida,Kazuyasu Nakamura,Kouji Matsushima,Ryuzo Ueda,Nobuo Hanai,Kenya Shitara +9 more
TL;DR: The results indicate that defucosylated antibodies with enhanced ADCC as well as potent antitumor activity in vivo are promising candidates for the novel antibody-based therapy.
Patent
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
Yutaka Kanda,Mitsuo Satoh,Kazuyasu Nakamura,Kazuhisa Uchida,Toyohide Shinkawa,Naoko Yamane,Emi Hosaka,Kazuya Yamano,Motoo Yamasaki,Nobuo Hanai +9 more
TL;DR: In this paper, a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the anti-antibody or the like.